Read More Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC

Read More Videos

Watch Now

Watch Now Trending

Read More

Read More

FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC

Novel Cancer Vaccine Receives FDA Orphan Drug Designation in Cutaneous Melanoma   Videos
 
Reducing Secondary Diagnostic Delay Through the Breast Clinical Reporting and Data System Trending

Chronic Lymphocytic Leukemia/Small-Cell Lymphoma: 6-Year Follow-Up on SEQUOIA and ALPINE LTE1
This program explores evolving strategies in the management of chronic lymphocytic leukemia (CLL), with insights from Drs. Ian Flinn and Danielle Brander. The discussion focuses on the integration of BTK inhibitors and BCL2-targeted therapy, particularly zanubrutinib and venetoclax, highlighting their efficacy, safety, and practical application. Experts emphasize individualized treatment, balancing disease characteristics, comorbidities, and patient preferences, while considering therapy duration and the role of minimal residual disease (MRD)-guided approaches.

Featured Video
Six-Year Outcomes in CLL and SLL: Insights from the SEQUOIA and ALPINE Trials
In this segment, experts review 6-year follow-up data from the SEQUOIA and ALPINE studies in CLL and SLL, with a focus on efficacy, safety, and treatment selection in the modern era.

FDA Accepts BLA for Ivonescimab Regimen in Pretreated EGFR-Mutated NSCLC

FDA OKs Larger Nelarabine Vial in T-Cell Leukemia and Lymphoma Populations

New Career Center Video:  
Learn how to build and strengthen your oncology referral network with expert insights from Tarita Thomas, MD, PhD, MBA, FACRO. Watch Increasing Your Oncology Referral Network now.

Videos











Trending
Innovation, Elevation, and Empowerment Through Integrative Care in Oncology
 

Recent advances in ER-positive/HER2-negative MBC
Education Alert
Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
0.50 CME / CE / ABIM MOC
Did you know that approximately 50% of breast cancer patients who have been exposed to an AI over time in the metastatic setting develop an ESR1 mutation?